Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senexis, Alzhyme collaborate for new Alzheimer’s test

This article was originally published in Clinica

Executive Summary

UK drug development firm Senexis has agreed to work with Australian biopharmaceutical company Alzhyme in order to develop a new diagnostic test for the early detection of Alzheimer’s disease. Cambridge, UK-based Senexis said that the new test would be designed for routine detection of disease biomarkers in the blood. “In spite of the attention Alzheimer’s receives, there is a significant medical need for the early detection of the condition,” said Senexis CEO Mark Treherne. The incidence of the disease is widely expected to double over the next two decades – in the US alone, five million people currently suffer from Alzheimer’s. Financial details of the collaboration were not revealed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041026

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel